A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients

A Randomized, Double-Blind, Paralleled, Active Controlled, Multi-Center Study of the Efficacy and Safety of 5mg Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder

To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid

Inclusion Criteria:

• Patients willing and able to complete the micturition diary correctly
• Patients experiencing frequency of micturition as verified in the diary
• Patients experiencing significant post void residual volume
• OAB symptoms including urinary frequency, urgency or urge incontinence for 3 months or more.

Exclusion Criteria:

• Significant post void residual volume
• Patients with indwelling catheters or practicing intermittent self- catheterization
• Known or suspected hypersensitivity to solifenacin succinate or other anticholinergics or lactose